"hCG priming" effect in controlled ovarian stimulation through a long protocol

Reproductive Biology and Endocrinology

Volumn 7, Issue , 2009, Pages 91-

  Beretsos, Panagiotis ^a   Partsinevelos, George A ^a   Arabatzi, Eleni ^a   Drakakis, Peter ^a   Mavrogianni, Depy ^a   Anagnostou, Elli ^a   Stefanidis, Kostas ^a   Antsaklis, Aris ^a   Loutradis, Dimitris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; PROLACTIN; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; EMBRYO DEVELOPMENT; FEMALE; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; OOCYTE DEVELOPMENT; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; CHORIONIC GONADOTROPIN; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; EMBRYO TRANSFER; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MALE; OVULATION INDUCTION; PILOT PROJECTS; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 71049189581     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-7-91     Document Type: Article

References (44)

1. Loutradis D, Drakakis P, Vomvolaki E, Antsaklis A. Different ovarian stimulation protocols for women with diminished ovarian reserve. J Assist Reprod Genet 2007, 24(12):597-611. 10.1007/s10815-007-9181-2, 18034299.
2. Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 2001, 179(1-2):39-46. 10.1016/S0303-7207(01)00469-5, 11420129.
3. Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsboll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod 2006, 21(10):2593-2600. 10.1093/humrep/del221, 16785262.
4. Shoham Z, Schacter M, Loumaye E, Weissman A, MacNamee M, Insler V. The luteinizing hormone surge - the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995, 64(2):237-251.
5. Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004, 82(6):1521-1526. 10.1016/j.fertnstert.2004.06.041, 15589853.
6. Fleming R, , Durnerin IC, Erb K, Hillier SG, Hugues J-N, Lyall H, Rasmussen PE, Thong J, Traynor I, Westergaard LG. on behalf of the 'Luveris Pre-treatment Group' Pre-treatment with rhLH: respective effects on antral follicular count and ovarian response to rhFSH. Hum Reprod 2006, 21(Supp 1):i54.
7. Durnerin CI, Erb K, Fleming R, Hillier H, Hillier SG, Howles CM, Hugues JN, Lass A, Lyall H, Rasmussen P. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008, 23(2):421-426. 10.1093/humrep/dem388, 18084048.
8. Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999, 84(1):228-232. 10.1210/jc.84.1.228, 9920089.
9. Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril 2001, 75(3):519-524. 10.1016/S0015-0282(00)01745-3, 11239535.
10. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000, 15(5):1003-1008. 10.1093/humrep/15.5.1003, 10783342.
11. Drakakis P, Loutradis D, Kallianidis K, Liapi A, Milingos S, Makrigiannakis A, Dionyssiou-Asteriou A, Michalas S. Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET. Eur J Obstet Gynecol Reprod Biol 2005, 121(1):77-80. 10.1016/j.ejogrb.2004.12.021, 15989987.
12. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, Wilding M, Varricchio MT, Borrelli AL, Conforti S. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol (Oxf) 2004, 60(5):637-643. 10.1111/j.1365-2265.2004.02027.x, 15104569.
13. De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, De Palo R, Ranieri A, Colacurci N, Mollo A. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005, 20(2):390-396. 10.1093/humrep/deh625, 15576390.
14. Drakakis P, Loutradis D, Kallianidis K, Bletsa R, Milingos S, Dionyssiou-Asteriou A, Michalas S. A comparative study of the effect of ovarian stimulation protocols with different gonadotropin preparations on the biological and clinical parameters of the outcome of intracytoplasmic sperm injection. Clin Exp Obstet Gynecol 2002, 29(4):286-289.
15. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984, 2(8414):1284-1285. 10.1016/S0140-6736(84)92840-X, 6150318.
16. Mochtar MH, Van der V, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007, (2):CD005070.
17. Huirne JA, Lambalk CB, van Loenen AC, Schats R, Hompes PG, Fauser BC, Macklon NS. Contemporary pharmacological manipulation in assisted reproduction. Drugs 2004, 64(3):297-322. 10.2165/00003495-200464030-00005, 14871171.
18. Branigan EF, Estes A. Use of micro-dose human chorionic gonadotropin (hCG) after clomiphene citrate (CC) to complete folliculogenesis in previous CC-resistant anovulation. Am J Obstet Gynecol 2005, 192(6):1890-1894. discussion 1894-1896, 10.1016/j.ajog.2005.02.072, 15970844.
19. Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002, 87(3):1156-1161. 10.1210/jc.87.3.1156, 11889180.
20. Koichi K, Yukiko N, Shima K, Sachiko S. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol. J Assist Reprod Genet 2006, 23(5):223-228. 10.1007/s10815-006-9036-2, 16786420.
21. Serafini P, Yadid I, Motta EL, Alegretti JR, Fioravanti J, Coslovsky M. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril 2006, 86(4):830-838. 10.1016/j.fertnstert.2006.02.110, 16963040.
22. Venetis CA, Kolibianakis EM, Tarlatzi TB, Tarlatzis BC. Benefits of luteinizing hormone activity in ovarian stimulation for IVF. Reprod Biomed Online 2009, 18(Suppl 2):31-36.
23. Weissman A, Lurie S, Zalel Y, Goldchmit R, Shoham Z. Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. Gynecol Endocrinol 1996, 10(4):273-276. 10.3109/09513599609012319, 8908528.
24. Yen SS, Llerena O, Little B, Pearson OH. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab 1968, 28(12):1763-1767. 10.1210/jcem-28-12-1763, 5699949.
25. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, Zygmunt M. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril 2005, 84(2):275-284. 10.1016/j.fertnstert.2005.02.033, 16084861.
26. Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, Parmegiani L, Pelusi G, DeAloysio D. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002, 8(6):543-557. 10.1093/humupd/8.6.543, 12498424.
27. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988, 159(1):210-215.
28. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998, 13(7):1788-1792. 10.1093/humrep/13.7.1788, 9740424.
29. Loutradis D, Drakakis P, Kallianidis K, Milingos S, Dendrinos S, Michalas S. Oocyte morphology correlates with embryo quality and pregnancy rate after intracytoplasmic sperm injection. Fertil Steril 1999, 72(2):240-244. 10.1016/S0015-0282(99)00233-2, 10438988.
30. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001, 86(6):2607-2618. 10.1210/jc.86.6.2607, 11397861.
31. Falck B. Site of production of oestrogen in rat ovary as studied in micro-transplants. Acta Physiol Scand Suppl 1959, 47(163):1-101.
32. Sasano H, Okamoto M, Mason JI, Simpson ER, Mendelson CR, Sasano N, Silverberg SG. Immunolocalization of aromatase, 17 alpha-hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary. J Reprod Fertil 1989, 85(1):163-169.
33. Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Hum Reprod 2000, 15(9):1882-1883. 10.1093/humrep/15.9.1882, 10966979.
34. Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, Tur R, Callejo J, Checa MA, Farre M. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum Reprod Update 2008, 14(6):571-582. 10.1093/humupd/dmn033, 2569859, 18812422.
35. Sungurtekin U, Jansen RP. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate. Fertil Steril 1995, 63(3):663-665.
36. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril 2001, 76(3):543-549. 10.1016/S0015-0282(01)01973-2, 11532479.
37. Loumaye E, Engrand P, Howles CM, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997, 67(5):889-899. 10.1016/S0015-0282(97)81402-1, 9130895.
38. Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Hum Reprod 1996, 11(6):1209-1213.
39. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT, Pocognoli P. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab 1999, 84(8):2659-2663. 10.1210/jc.84.8.2659, 10443656.
40. Psychoyos A, . (ed) The implantation window: basic and clinical aspects. Rome 1993,
41. Peng X, Kim JJ, Fazleabas AT. Apoptosis and Differentiation in Baboon Stromal Cells: A role for Chorionic Gonadotropin (CG)?. Biol Reprod 2000, 62:307-308.
42. Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999, 13(6):806-811. 10.1210/me.13.6.806, 10379879.
43. Kilani Z, Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani L, Filicori M. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod 2003, 18(6):1194-1199. 10.1093/humrep/deg252, 12773445.
44. Huhtaniemi IT, Catt KJ. Differential binding affinities of rat testis luteinizing hormone (LH) receptors for human chorionic gonadotropin, human LH, and ovine LH. Endocrinology 1981, 108(5):1931-1938. 10.1210/endo-108-5-1931, 6260468.